acute kidney tubular necrosis: Acute renal failure caused by the cell death of the renal tubules. Causes include nephrotoxins, cytotoxic drugs, and antibiotics.
Drug- and heavy-metal-induced tubulo-interstitial and tubular conditions
DOID EFO Endpoint Browser PheWeb
N14_DRUGSANDHEAVYMETAL
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
132 |
4. Check minimum number of eventsNone |
132 |
5. Include endpointsNone |
132 |
6. Filter based on genotype QC (FinnGen only) |
106 |
Control definitions (FinnGen only)
- Control exclude
- N14_RENALTUB
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- N10-N16
- Name in latin
- Condiciones tubulo-interstitiales et tubulares ex medicamentis et metallis gravibus
Similar endpoints
↥List of similar endpoints to
Drug- and heavy-metal-induced tubulo-interstitial and tubular conditions
based on the number of shared cases.
Similar with more cases:
- Renal tubulo-interstitial diseases
- All kidney diseases
- Genitourinary diseases
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 684 | 289 | 389 |
| Only index persons | 549 | 241 | 308 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 64.13 | 65.48 | 62.95 |
| Only index persons | 62.02 | 64.29 | 60.25 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 106 | 44 | 62 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 60.32 | 62.43 | 58.82 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 111
- Matched controls
- 1110
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N14.1
ICD-10 Finland
Nephropathy induced by other drugs, medicaments and biological substances
+∞
80.2
67
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
165.9
53.7
53
6
N17.9
ICD-10 Finland
Acute renal failure, unspecified
602.8
42.1
39
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
22.9
41.9
34
21
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
10.6
31.0
44
65
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
+∞
27.2
25
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
35.4
25.8
33
13
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
+∞
22.7
21
*
N19
ICD-10 Finland
Unspecified kidney failure
39.0
21.8
27
9
TK800
NOMESCO Finland
Hemodialysis
135.7
21.4
22
*
Z49.1
ICD-10 Finland
Extracorporeal dialysis
+∞
20.4
19
*
N14.2
ICD-10 Finland
Nephropathy induced by unspecified drug, medicament or biological substance
+∞
20.4
19
*
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
+∞
18.2
17
*
A11CC03
ATC
alfacalcidol; systemic
+∞
18.2
17
*
N14.0
ICD-10 Finland
Analgesic nephropathy
+∞
17.1
16
*
N18.8
ICD-10 Finland
Other chronic renal failure
70.8
16.3
18
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
6.6
14.8
28
54
B03XA02
ATC
darbepoetin alfa; parenteral
49.7
14.6
17
*
L04AA06
ATC
mycophenolic acid; systemic
61.6
14.2
16
*
N05AN01
ATC
lithium; oral
25.1
13.9
19
9
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
7.6
13.9
22
35
N11.8
ICD-10 Finland
Other chronic tubulo-interstitial nephritis
+∞
13.8
13
*
N18.0
ICD-10 Finland
End-stage renal disease
+∞
13.8
13
*
C03CA01
ATC
furosemide; systemic
4.4
13.5
57
215
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.0
13.5
28
59
N03AG01
ATC
valproic acid; systemic, rectal
7.4
13.0
21
34
KA1AE
NOMESCO Finland
Kidney ultrasound examination
36.9
13.0
16
5
127
Kela drug reimbursment
Transplant complication
79.2
12.9
14
*
N18.5
ICD-10 Finland
Chronic kidney disease, stage 5
+∞
12.7
12
*
Z49.0
ICD-10 Finland
Preparatory care for dialysis
+∞
12.7
12
*
A12AA04
ATC
calcium carbonate; oral
145.8
12.7
13
*
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
145.8
12.7
13
*
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
52.9
12.2
14
*
JN4AD
NOMESCO Finland
Body CT examination
5.2
11.7
29
71
L04AX01
ATC
azathioprine; systemic
16.2
11.4
18
13
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.1
11.1
77
397
V03AE01
ATC
polystyrene sulfonate; oral
+∞
10.6
10
*
Z94.0
ICD-10 Finland
Kidney transplant status
+∞
10.6
10
*
N05CD07
ATC
temazepam; oral
4.8
10.4
28
73
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.3
10.1
23
52
L04AA01
ATC
[U] ciclosporin
60.4
9.8
11
*
205
Kela drug reimbursment
Chronic hypertension
3.6
9.8
47
187
N06AB04
ATC
citalopram; systemic
3.9
9.6
38
132
N17.0
ICD-10 Finland
Acute renal failure with tubular necrosis
+∞
9.5
9
*
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
9.5
9
*
N17.8
ICD-10 Finland
Other acute renal failure
+∞
9.5
9
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.0
9.4
34
111
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
8.5
9.2
20
28
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
10.0
9.2
18
21
M04AA01
ATC
allopurinol; systemic
4.1
9.1
30
91
N05AA02
ATC
levomepromazine; systemic
12.2
9.1
16
15
R50.9
ICD-10 Finland
Fever, unspecified
4.0
8.8
31
99
N05AH03
ATC
olanzapine; systemic
5.6
8.7
18
37
L04AD01
ATC
ciclosporin; systemic
22.2
8.7
12
6
H02AB04
ATC
methylprednisolone; systemic
3.9
8.5
30
96
ZXE10
NOMESCO Finland
More than one and less than three hours
3.2
8.4
56
267
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
+∞
8.4
8
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.3
8.3
46
197
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
14.5
8.1
13
10
A41.9
ICD-10 Finland
Sepsis, unspecified
14.5
8.1
13
10
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.1
8.1
55
265
ZXE00
NOMESCO Finland
One hour or less
3.1
8.0
59
297
3AC01, ,
NOMESCO Finland
48.5
7.8
9
*
R33
ICD-10 Finland
Retention of urine
4.9
7.8
19
45
J01MA02
ATC
ciprofloxacin; systemic
3.1
7.8
56
276
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
12.1
7.5
13
12
N18.4
ICD-10 Finland
Chronic kidney disease, stage 4
85.6
7.5
8
*
B03XA03
ATC
methoxy polyethylene glycol-epoetin beta; parenteral
+∞
7.4
7
*
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
+∞
7.4
7
*
N11.9
ICD-10 Finland
Chronic tubulo-interstitial nephritis, unspecified
+∞
7.4
7
*
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
+∞
7.4
7
*
F31.7
ICD-10 Finland
Bipolar affective disorder, currently in remission
18.1
6.9
10
6
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
4.1
6.8
21
60
R4190
NOMESCO Finland
Nutritional therapy
9.6
6.8
13
15
JN3AD
NOMESCO Finland
Abdominal CT examination
4.0
6.7
21
61
F25.0
ICD-10 Finland
Schizoaffective disorder, manic type
73.9
6.5
7
*
L04AD02
ATC
tacrolimus; systemic
73.9
6.5
7
*
208
Kela drug reimbursment
Ulcerative colitis and Crohn's disease
10.2
6.5
12
13
K51.5
ICD-10 Finland
Left sided colitis
12.0
6.5
11
10
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.0
6.4
15
24
Z2446
NOMESCO Finland
Social worker
4.6
6.3
16
39
F31.30
ICD-10 Finland
Bipolar disorder Depressive episode without somatic syndrome
28.5
6.3
8
*
N05CF01
ATC
zopiclone; oral
2.8
6.3
50
254
PBU84
NOMESCO Finland
Plastic repair of arteriovenous fistula from artery of upper extremity
+∞
6.3
6
*
320
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
+∞
6.3
6
*
PBM10
NOMESCO Finland
Closure of arteriovenous fistula of radial artery
+∞
6.3
6
*
N25.1
ICD-10 Finland
Nephrogenic diabetes insipidus
+∞
6.3
6
*
N14.4
ICD-10 Finland
Toxic nephropathy, not elsewhere classified
+∞
6.3
6
*
A03FA01
ATC
metoclopramide; systemic, rectal
3.1
6.3
33
134
N05AX12
ATC
aripiprazole; systemic
9.5
6.2
12
14
K51.9
ICD-10 Finland
Ulcerative colitis, unspecified
10.9
6.2
11
11
ZXD10
NOMESCO Finland
Scheduled procedure
2.7
6.0
53
283
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
42
50
12.90
35.11
9.0
1.5
146.75
61.10
ng/l
3.09
36
45
57
157
6.41
21.52
8.5
2.8
0.83
0.81
mmol/l
0.33
57
152
29
39
9.71
21.47
12.1
1.4
22.66
25.18
mmol/l
2.77
29
39
94
458
7.87
17.34
29.4
5.4
1.22
1.21
mmol/l
0.33
76
392
30
55
7.10
16.78
16.6
7.7
24.05
25.31
mmol/l
0.76
30
55
37
110
4.55
11.83
7.7
3.4
—
—
—
0
0
23
29
9.71
11.31
5.8
2.5
24.15
26.23
mmol/l
1.64
23
29
68
321
3.89
11.18
8.6
4.0
29.41
9.15
mg/mmol
1.31
57
204
18
15
14.05
10.80
10.1
1.3
12.18
8.03
pmol/l
0.66
18
15
26
64
5.00
10.38
2.5
1.5
—
—
—
0
0
57
251
3.61
10.19
4.5
2.6
399.82
347.03
umol/l
2.48
51
214
43
159
3.78
10.00
2.9
1.7
—
—
—
0
0
24
57
5.10
9.96
5.5
3.2
1.37
2.48
mmol/l
0.68
18
48
59
271
3.51
9.78
8.0
2.8
0.22
0.30
e6/l
0.24
51
197
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
18
21
10.00
9.23
3.9
1.5
0.24
0.29
iu/ml
—
11
9
51
223
3.38
8.99
3.5
2.1
3.15
2.88
mg/l
0.27
42
192
25
68
4.45
8.76
7.1
2.9
5.38
5.26
kpa
0.23
25
68
87
538
3.85
8.47
21.3
10.0
4.23
3.80
e9/l
0.74
81
479
24
66
4.36
8.27
5.0
3.6
34.21
64.96
ml/min/173m2
3.78
14
24
33
115
3.66
8.20
2.5
1.6
—
—
—
0
0
34
121
3.61
8.19
2.4
1.5
—
—
—
0
0
18
27
7.74
7.99
1.4
4.7
1.21
2.62
ratio
—
8
11
14
15
10.49
7.54
1.6
1.3
—
—
—
0
0
17
26
7.52
7.46
1.6
1.5
—
—
—
0
0
54
267
2.99
7.42
2.3
1.6
15.30
22.91
nmol/l
5.23
44
213
14
16
9.83
7.30
1.6
1.6
—
—
—
0
0
36
148
3.12
6.76
2.6
1.6
1268.10
1255.64
nmol/l
0.02
29
115
6
0
+∞
6.30
11.5
0.0
4.38
—
mmol/l
—
6
0
12
14
9.45
6.23
1.7
1.1
—
—
—
0
0
32
129
3.08
6.16
17.4
6.8
105.16
103.57
mmol/l
0.81
32
129
17
46
4.18
5.90
9.8
2.1
1.19
1.43
%
0.35
17
46
17
46
4.18
5.90
9.0
2.1
0.59
0.59
%
0.00
17
46
10
10
10.84
5.66
2.4
1.4
87.40
90.41
%
—
10
10
13
22
6.54
5.41
2.2
1.4
—
—
—
0
0
34
154
2.74
5.22
5.5
2.4
0.63
0.98
e6/l
0.44
22
79
14
28
5.56
5.15
1.6
1.4
—
—
—
0
0
12
20
6.59
5.07
13.3
1.8
5.10
4.95
kpa
0.25
12
20
13
26
5.52
4.81
1.4
1.3
—
—
—
0
0
31
140
2.68
4.75
6.1
2.5
0.74
2.19
e6/l
0.77
19
66
11
18
6.65
4.74
1.9
1.3
—
—
—
0
0
92
688
2.97
4.70
6.8
4.2
21.63
11.34
mm/h
4.42
86
633
12
23
5.71
4.61
1.9
1.5
—
—
—
0
0
16
50
3.57
4.54
10.6
2.5
174.63
131.96
ng/l
0.24
16
45
12
26
5.04
4.20
1.4
1.2
—
—
—
0
0
8
10
8.51
4.13
1.9
1.2
—
—
—
0
0
7
7
10.56
4.07
1.3
1.1
—
—
—
0
0
12
28
4.67
3.95
1.4
1.2
—
—
—
0
0
10
19
5.67
3.93
1.5
1.2
—
—
—
0
0
72
505
2.21
3.84
8.4
3.4
0.00
0.00
estimate
-0.00
26
121
7
8
9.24
3.83
1.6
1.3
—
—
—
0
0
62
411
2.15
3.81
3.0
1.9
98.76
99.76
pmol/l
0.06
37
194
16
58
3.05
3.60
22.3
10.3
0.72
0.69
%
0.14
16
58
6
6
10.47
3.54
22.7
6.0
10.02
10.52
mg/l
—
6
6
12
32
4.08
3.51
1.3
1.7
1.14
1.18
g/l
0.14
12
32
12
32
4.08
3.51
1.2
1.7
0.25
0.23
g/l
0.28
12
32
72
517
2.12
3.46
8.4
3.5
0.04
0.00
estimate
0.49
27
109
71
509
2.10
3.40
8.5
3.5
0.00
0.00
estimate
-0.00
27
122
16
60
2.95
3.40
22.7
10.1
1.44
1.56
%
0.18
16
60
14
49
3.13
3.33
1.8
1.3
—
—
—
0
0
15
55
3.00
3.31
1.6
1.7
—
—
—
0
0
11
29
4.09
3.29
1.6
1.7
0.00
0.00
g/l
-0.00
11
24
10
24
4.47
3.28
1.5
1.2
—
—
—
0
0
8
15
5.65
3.25
1.0
1.1
—
—
—
0
0
8
15
5.65
3.25
1.0
1.1
—
—
—
0
0
6
8
7.84
3.09
1.7
1.1
—
—
—
0
0
6
8
7.84
3.09
1.7
1.1
—
—
—
0
0
33
186
2.10
2.96
2.6
1.8
465.85
417.15
pmol/l
0.43
27
155
46
296
1.95
2.85
9.1
3.5
0.00
0.03
estimate
0.50
22
111
11
34
3.48
2.82
1.6
2.1
0.00
0.62
g/l
0.75
11
28
9
24
3.99
2.74
2.0
1.6
—
—
—
0
0
17
75
2.50
2.67
3.0
3.3
36.88
31.89
u/l
0.25
17
56
86
695
2.05
2.58
6.3
4.3
14.82
14.85
pmol/l
0.04
81
632
6
12
5.22
2.43
1.0
1.2
—
—
—
0
0
5
8
6.48
2.39
1.6
1.0
—
—
—
0
0
56
403
1.79
2.33
6.9
4.0
35.12
41.80
ng/l
0.26
43
305
37
235
1.86
2.31
7.0
2.3
—
—
—
0
0
54
388
1.76
2.24
8.8
3.4
0.00
0.00
estimate
-0.00
23
103
5
9
5.75
2.23
1.6
2.0
—
—
—
0
0
5
10
5.18
2.09
1.6
1.9
—
—
—
0
0
5
10
5.18
2.09
1.6
1.9
—
—
—
0
0
12
52
2.47
1.95
4.4
3.7
3.57
4.46
pmol/l
3.20
12
45
7
22
3.32
1.91
1.3
1.3
—
—
—
0
0
9
35
2.71
1.85
2.4
1.4
—
0.10
—
0
7
6
18
3.46
1.77
1.2
2.1
—
—
—
0
0
59
455
1.63
1.75
4.2
2.6
—
—
estimate
—
0
0
5
15
3.44
1.54
1.2
1.5
—
—
—
0
0
15
81
1.98
1.48
4.5
2.9
8.69
7.48
ug/l
0.08
15
76
5
16
3.22
1.45
1.2
1.3
—
—
—
0
0
9
40
2.36
1.44
2.3
2.6
—
—
—
0
0
30
207
1.62
1.34
7.5
1.5
2.18
1.25
mg/l
0.65
25
168
40
297
1.54
1.32
9.6
3.1
0.00
0.00
estimate
-0.00
22
102
5
19
2.71
1.23
1.0
1.2
—
—
—
0
0
74
632
1.51
1.22
5.4
3.2
52.82
57.69
u/l
0.29
68
595
87
771
1.59
1.19
67.1
18.5
14.19
13.60
%
3.84
87
766
7
32
2.27
1.10
3.1
1.7
—
—
—
0
0
7
32
2.27
1.10
3.1
2.1
—
—
—
0
0
6
28
2.21
0.93
1.3
1.1
561.00
488.32
mg/l
—
6
28
99
921
1.69
0.92
58.8
14.2
24.64
23.28
mg/l
0.21
93
767
28
214
1.41
0.77
1.5
1.2
0.84
1.68
u/ml
—
9
61
62
540
1.34
0.75
3.8
3.0
—
—
—
0
0
0
20
0.00
0.61
0.0
1.1
—
1.84
—
0
11
15
110
1.42
0.52
1.7
1.4
—
—
—
0
0
26
210
1.31
0.51
6.2
3.4
1.01
1.02
kg/l
1.06
21
133
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.4
—
15.89
—
0
19
9
68
1.35
0.39
2.0
1.8
—
—
—
0
0
38
333
1.21
0.38
4.8
4.4
26.61
22.58
%
0.72
21
161
46
417
1.18
0.31
6.0
5.2
2.23
2.71
ug/l
0.24
40
368
10
75
1.37
0.31
1.9
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
92
897
1.15
0.16
5.5
4.4
1.44
1.28
mmol/l
1.17
83
812
12
107
1.14
0.09
2.0
2.2
13.05
14.54
nmol/l
0.26
12
100
92
934
0.91
0.08
6.8
5.2
1.36
1.45
mmol/l
1.42
83
852
93
940
0.93
0.04
6.8
5.3
4.25
4.56
mmol/l
2.78
85
866
89
900
0.94
0.04
10.2
6.5
40.45
39.55
mmol/mol
0.30
84
849
10
92
1.10
0.03
1.4
1.5
—
—
—
0
0
15
142
1.07
0.02
1.8
1.6
—
—
—
0
0
42
429
0.97
0.02
2.8
2.0
1.48
1.37
mmol/l
0.32
34
347
94
948
0.94
0.02
7.4
6.1
2.35
2.64
mmol/l
3.28
86
870
18
173
1.05
0.01
1.1
1.3
22.47
31.45
iu/ml
—
6
55
16
154
1.05
0.00
1.0
1.3
8.14
11.15
u/ml
—
5
55
11
108
1.02
0.00
18.6
7.6
—
—
—
0
0
27
269
1.00
0.00
4.4
3.1
0.98
0.77
ug/l
0.74
20
171
91
914
0.98
0.00
7.5
5.1
6.25
5.98
mmol/l
0.96
85
834
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.4
—
30.89
—
0
9
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.6
—
13.09
—
0
8
Mortality – FinRegistry
↥Association
Association between endpoint N14_DRUGSANDHEAVYMETAL and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| N14_DRUGSANDHEAVYMETAL | 3.362 [2.25, 5.03] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.349 |
During the follow-up period (1.1.1998 — 31.12.2019), 99 out of 233 females with N14_DRUGSANDHEAVYMETAL died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| N14_DRUGSANDHEAVYMETAL | 3.426 [2.35, 4.99] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 143 out of 306 males with N14_DRUGSANDHEAVYMETAL died.
Mortality risk
Mortality risk for people of age
years, who have N14_DRUGSANDHEAVYMETAL.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.39% | 0.579% |
| 5 | 1.968% | 3.236% |
| 10 | 4.881% | 8.516% |
| 15 | 9.146% | 16.055% |
| 20 | 15.779% | 26.508% |
Relationships between endpoints
↥Index endpoint: N14_DRUGSANDHEAVYMETAL – Drug- and heavy-metal-induced tubulo-interstitial and tubular conditions
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data